| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Immatics N.V (NASDAQ: IMTX)
IMTX Technical Analysis
3
| As on 9th Jun 2023 IMTX STOCK Price closed @ 11.23 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.69 & Buy for SHORT-TERM with Stoploss of 10.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IMTXSTOCK Price
| Open | 10.85 | Change | Price | % |
| High | 11.33 | 1 Day | 0.44 | 4.08 |
| Low | 10.84 | 1 Week | 1.38 | 14.01 |
| Close | 11.23 | 1 Month | 4.37 | 63.70 |
| Volume | 496200 | 1 Year | -1.06 | -8.62 |
| 52 Week High 13.44 | 52 Week Low 5.92 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IMTX Daily Charts |
IMTX Intraday Charts |
Whats New @ Bazaartrend |
IMTX Free Analysis |
|
|
IMTX Important Levels Intraday
| RESISTANCE | 12.17 |
| RESISTANCE | 11.87 |
| RESISTANCE | 11.68 |
| RESISTANCE | 11.50 |
| SUPPORT | 10.96 |
| SUPPORT | 10.78 |
| SUPPORT | 10.59 |
| SUPPORT | 10.29 |
IMTX Forecast May 2024
| 4th UP Forecast | 18.69 |
| 3rd UP Forecast | 16.3 |
| 2nd UP Forecast | 14.82 |
| 1st UP Forecast | 13.34 |
| 1st DOWN Forecast | 9.12 |
| 2nd DOWN Forecast | 7.64 |
| 3rd DOWN Forecast | 6.16 |
| 4th DOWN Forecast | 3.77 |
IMTX Weekly Forecast
| 4th UP Forecast | 14.78 |
| 3rd UP Forecast | 13.64 |
| 2nd UP Forecast | 12.94 |
| 1st UP Forecast | 12.23 |
| 1st DOWN Forecast | 10.23 |
| 2nd DOWN Forecast | 9.52 |
| 3rd DOWN Forecast | 8.82 |
| 4th DOWN Forecast | 7.68 |
IMTX Forecast2024
| 4th UP Forecast | 27.13 |
| 3rd UP Forecast | 22.03 |
| 2nd UP Forecast | 18.88 |
| 1st UP Forecast | 15.73 |
| 1st DOWN Forecast | 6.73 |
| 2nd DOWN Forecast | 3.58 |
| 3rd DOWN Forecast | 0.43 |
| 4th DOWN Forecast | -4.67 |
Immatics N.V ( NASDAQ USA Symbol : IMTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IMTX Business Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany. Address: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service